Mabpharm Ltd. (2181) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

China YuHua Education Corp. Ltd.

Greatview Aseptic Packaging Co., Ltd.

China New Higher Education Group Ltd.

FSE Lifestyle Services Ltd.

Hangzhou Tigermed Consulting Co., Ltd.

XJ International Holdings Co., Ltd.

China Conch Environment Protection Holdings Ltd.

Mabpharm Ltd.

Jiangsu Recbio Technology Co., Ltd.

Shimao Services Holdings Ltd.

C-Link Squared Ltd.

Why is Mabpharm Ltd. ?

Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 0%

Poor long term growth as Operating profit has grown by an annual rate 13.61% of over the last 5 years
High Debt Company with a Debt to Equity ratio (avg) at times

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -5.66%, its profits have risen by 40.2%

Consistent Underperformance against the benchmark over the last 3 years

Along with generating -5.66% returns in the last 1 year, the stock has also underperformed Hang Seng Hong Kong in each of the last 3 annual periods

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Miscellaneous)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Mabpharm Ltd. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Mabpharm Ltd.

-100.0%

0.45

82.04%

Hang Seng Hong Kong

8.25%

0.41

19.93%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

240.54%

EBIT Growth (5y)

13.61%

EBIT to Interest (avg)

-43.95

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

1.51

Sales to Capital Employed (avg)

0.35

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

34.86

EV to EBIT

-26.70

EV to EBITDA

-55.16

EV to Capital Employed

14.50

EV to Sales

12.29

PEG Ratio

Dividend Yield

ROCE (Latest)

-54.30%

ROE (Latest)

-145.97%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bullish

Dow Theory

Mildly Bearish

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

26What is working for the Company

OPERATING CASH FLOW(Y)

Highest at HKD 130.68 MM

ROCE(HY)

Highest at -25.72%

DEBTORS TURNOVER RATIO(HY)

Highest at 3.64 times

RAW MATERIAL COST(Y)

Fallen by -148.63% (YoY

NET SALES(Q)

Highest at HKD 294.51 MM

OPERATING PROFIT(Q)

Highest at HKD 37.05 MM

OPERATING PROFIT MARGIN(Q)

Highest at 12.58 %

PRE-TAX PROFIT(Q)

Highest at HKD 3.11 MM

NET PROFIT(Q)

Highest at HKD 3.11 MM

EPS(Q)

Highest at HKD 0

-3What is not working for the Company

DEBT-EQUITY RATIO (HY)

Highest at 213.27 %

Here's what is working for Mabpharm Ltd.

Net Sales

At HKD 294.51 MM has Grown at 150.53%

Year on Year (YoY)

MOJO Watch

Near term sales trend is extremely positive

Net Sales (HKD MM)

Operating Cash Flow

Highest at HKD 130.68 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (HKD MM)

Pre-Tax Profit

At HKD 3.11 MM has Grown at 102.96%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (HKD MM)

Debtors Turnover Ratio

Highest at 3.64 times and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Net Sales

Highest at HKD 294.51 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (HKD MM)

Operating Profit

Highest at HKD 37.05 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (HKD MM)

Operating Profit Margin

Highest at 12.58 %

in the last five periods

MOJO Watch

Company's profit margin has improved

Operating Profit to Sales

Pre-Tax Profit

Highest at HKD 3.11 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (HKD MM)

Net Profit

Highest at HKD 3.11 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (HKD MM)

Net Profit

At HKD 3.11 MM has Grown at 102.96%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is positive

Net Profit (HKD MM)

EPS

Highest at HKD 0

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (HKD)

Raw Material Cost

Fallen by -148.63% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Mabpharm Ltd.

Debt-Equity Ratio

Highest at 213.27 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio